SecProbe.io

CORRESP
1
filename1.htm

corresp

    One Financial Center

Boston, MA 02111

617-542-6000

617-542-2241 fax

    Megan N. Gates | 617 348 4443 | mgates@mintz.com

    www.mintz.com

April
15, 2010

Via EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 4720

100 F Street, N.E.

Washington, DC 20549

Attention: Jennifer Riegel, Esq.

    Re:

     OXiGENE, Inc.

Registration Statement on Form S-3

Filed March 31, 2010

File No. 333-165826

Ladies and Gentlemen:

     On behalf of OXiGENE, Inc. (the “Company”), we are hereby filing with the Staff (the “Staff”)
of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”)
this response to the letter dated April 6, 2010 from Jeffrey Riedler, Esq. of the Staff to Peter J.
Langecker, M.D., Ph.D., the Company’s Chief Executive Officer (the “Comment Letter”) relating to
the above-captioned Registration Statement (the “Registration Statement”). The Registration
Statement relates to the resale of securities issued in a private placement of common stock, $0.01
par value per share, and warrants to purchase common stock (the “Offering”).

     As requested, the comments and responses set forth below are keyed to the numbering of the
comments and the headings used in the Comment Letter and are based upon information provided to
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. by the Company.

General

     1. Comment: You are seeking to register the resale of your Series A Warrants and Series
C Warrants, but not the resale of your Series B Warrants and Series D Warrants. Please tell us why
you are not seeking to register the resale of your Series B Warrants and Series D Warrants.

     Response: The Company is not seeking to register the resale of its Series B Warrants and
Series D Warrants because, by agreement with the holders of the securities purchased in the
Offering, the Company is not obligated to apply to list the Series B Warrants and the Series D
Warrants for trading on the Over-the-counter Bulletin Board (the “OTCBB”). By contrast, the

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

Boston | Washington | New York | Stamford | Los Angeles | Palo Alto | San Diego | London

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

OXiGENE, Inc.

April 15, 2010

Page 2

Company
is obligated to apply to list the Series A Warrants and the Series C Warrants on the OTCBB. In
order to be accepted to trade on the OTCBB, a security must be registered under the Securities Act
of 1933, as amended. As a result, in order to meet the obligation to have the Series A Warrants and
the Series C Warrants listed for trading on the OTCBB, the Company seeks to have the resale of the
Series A Warrants and the Series C Warrants registered on the Registration Statement.

     2. Comment: Your legal opinion states, “Series C Warrants have been duly authorized and
reserved for issuance, and, when issued upon exercise of the Series B Warrants in accordance with
their terms, will be validly issued and constitute legal, valid and binding agreements of the
Company.” Since your Series C Warrants will not be issued until the Series B Warrants are
exercised, it is premature to register the resale of the Series C warrants and the shares
underlying the Series C warrants at this time. Please revise your registration statement to remove
from registration the Series C Warrants and the shares of common stock underlying these Series C
Warrants. Please also revise your disclosure to clarify that these Series C Warrants are not
outstanding and are not being registered for resale.

     Response: Please note that the Series C Warrants were issued at the closing of the Offering,
as indicated in the description of the offering on page 5 of the prospectus (under “Private
Placement of Common Shares and Warrants.” The disclosure in our legal opinion incorrectly conveyed
the impression that the Series C Warrants had not been issued, whereas in fact they have been
issued. The Series C Warrants are simply not exercisable until the Series B Warrants have
been exercised. We have revised our legal opinion to clarify that the Series C Warrants have indeed
been issued and to correct this misimpression.

     3. Comment: You are seeking to register the resale of the shares of common stock underlying
some of the Series A Warrants, Series B Warrants, Series C Warrants and Series D Warrants, but not
all the shares of common stock underlying these warrants. Please revise your disclosure throughout
your registration statement, including your registration fee table and selling securityholder
table, to clearly state the number of shares of common underlying your
Series A Warrants that are registered for resale on this registration statement. Similar
disclosure should be made for the shares of common stock underlying your Series B Warrants and
Series D Warrants.

     Response: The Company has revised the disclosure throughout the registration statement, including in the
registration fee table and the selling securityholder table, to indicate the specific numbers of
shares of common stock underlying each of the Series A Warrants, Series B Warrants, Series C
Warrants and Series D Warrants that are being registered for resale on this registration statement.

Private Placement of Common Shares and Warrants, page 5

     4. Comment: In connection with your Series B Warrants, Series C Warrants and Series D
Warrants you refer to “the date on which [your] stockholders approve the issuance of shares in the
transaction.” In each instance, please revise your disclosure to clarify whether you are seeking
to have your stockholders approve the exercise of the respective warrants or the private placement
that occurred on March 12, 2010. Please also disclose why you are seeking to have

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

OXiGENE, Inc.

April 15, 2010

Page 3

your stockholders approve the issuance of shares. For example, are you seeking this approval in
connection with a stock exchange rule and/or a change of control provision?

     Response: We have revised the disclosure on page 7 of the prospectus to clarify further
that the Company will be seeking stockholder approval of the issuance of shares pursuant to the
exercise of the warrants issued in connection with the Offering in order to satisfy NASDAQ
Marketplace Rule 5635(d), which requires stockholder approval of the issuance of shares in an
amount exceeding 19.9% of a listed company’s issued and outstanding shares at a price that is less
than the greater of the book or market value of such shares.

     5. Comment: You disclose that your Series B Warrants and Series C Warrants are exercisable
upon the earlier of the six month anniversary of the closing date or the date on which your
stockholders approve the transaction. Since these warrants may be exercisable prior to date upon
which your stockholders approve the transaction, please expand your disclosure to disclose the
consequences if the shares of common stock underlying the warrants are issued without stockholder
approval.

     Response: We have revised the disclosure on pages 6 and 7 of the prospectus in order to
clarify that the Company will not be permitted to issue shares upon exercise of the warrants if
such issuance would cause the Company to exceed the number of shares of common stock that are
issuable without violating NASDAQ Marketplace Rule 5635(d), as described above in the response to
Comment 4.

Incorporation of Certain Documents by Reference, page 24

     6. Comment: We note that your registration statement incorporates by reference materials
from your Annual Report on Form 10-K for the year ended December 31, 2009. This filing does not
contain information in Part III that is required by Form 10-K. Please amend your filing to include
Part III information, or file a proxy statement to incorporate this information into your filing by
reference. Your filing must be complete before we take final action on the registration statement.

     Response: The Company supplementally advises the Staff that it intends to
file an amendment to its Annual Report on Form 10-K, in order to incorporate the
information required by Part III of the Annual Report on Form 10-K into the Registration Statement
by reference, within the next few business days.

     7. Comment: Please revise your filing to incorporate by reference your Form 8-K filed on
April 5, 2010. See Question 123.05 of the Securities Act Forms Compliance and Disclosure
Interpretations.

     Response: The Company has revised the Registration Statement to incorporate by reference the Form 8-K filed on April 5, 2010.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

OXiGENE, Inc.

April 15, 2010

Page 4

Exhibit 5.1

     8. Comment: Please revise your legal opinion to include all securities which you are seeking
to register on your registration statement. For example, it does not appear that you have included
your 6,578,945 Series A Warrants to purchase common stock or the Rights to purchase common stock in
this legal opinion.

     Response: We have revised our legal opinion to include all securities which the Company is
seeking to register on the Registration Statement.

     In addition, the Company acknowledges that:

    •

    the Company is responsible for the adequacy and accuracy of the disclosure in the
filing;

    •

    Staff comments or changes to disclosure in response to Staff comments in the filings
reviewed by the Staff do not foreclose the Commission from taking any action with
respect to the filing; and

    •

    the Company may not assert Staff comments as a defense in any proceeding initiated
by the Commission or any person under the federal securities laws of the United States.

     We hope that the above response will be acceptable to the Staff. If you have any questions or
comments regarding the foregoing, kindly contact the undersigned at (617) 348-4443. Thank you for
your time and attention.

Sincerely,

/s/
Megan N. Gates

Megan N. Gates

    cc:

    Securities and Exchange Commission

         Jeffrey Riedler, Esq.

         Suzanne Hayes, Esq.

    OXiGENE, Inc.

         Peter J. Langecker, M.D., Ph.D.

         D. Clinton Webb, Esq.

         James B. Murphy

    Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

         Jonathan L. Kravetz, Esq.